Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 3Respiratory Tract Diseases 1Osteosarcoma 1Neoplasms 1Neoplasm Metastasis 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1EGFR-mutant Non-small Cell Lung Cancer 1Brain Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 12Specimen Handling 9cabozantinib 8X-Rays 8Magnetic Resonance Spectroscopy 8fludarabine 7Phantoms, Imaging 7Biopsy 7Temozolomide 6Gemcitabine 5regorafenib 4pembrolizumab 4Vincristine 4Nuclear Medicine Department, Hospital 4Nivolumab 4Methotrexate 4Doxorubicin 4olaparib 3irinotecan sucrosofate 3fludarabine phosphate 3dinutuximab 3Zoledronic Acid 3Surveys and Questionnaires 3Irinotecan 3Ifosfamide 3Cisplatin 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × Gefitinib × 1 year × Clear all
NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
45 enrolled
Sarcoma

Neoplasm Metastasis, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡